4 ms·
Clinician impact and financial cost to NHS of litigation over pregabalin
- DanBC 9y agoThe full title is "The clinician impact & financial cost to the NHS of litigation over pregabalin: a cohort study in English primary care | bioRxiv" - too long for the 80 char limit.
- DanBC 9y agoOne of the authors of this piece has some involvement with OpenPrescribing. In England all prescription info is open. We can use that to try to reduce prescribing of meds that have more effective alternatives, or that have cheaper as effective alternatives, or that are dangerous. https://openprescribing.net/ https://openprescribing.net/
- cirrus-clouds 9y agoAnother example: anti-cancer drug Avastis has been found to be effective against blindness in old age (wet macular degeneration). The current drug for preventing wet macular degeneration is Lucentis, which costs 10 times more than Avastis. Twelve NHS clinical commissioning groups (CCGs) have recommended switching to the cheaper (and just as effective) Avastis drug. But Novartis and Bayer, who market the more expensive Lucentis, have threaten legal action over the use of the cheaper drug. https://www.theguardian.com/society/2017/nov/01/drug-giants-threaten-nhs-with-legal-action-over-cheaper-drug-that-could-save-84m-a-year https://www.theguardian.com/society/2017/nov/01/drug-giants-...
- dm319 9y agoAnd this is the concern of agreements like TTIP, where companies can sue government policies that result in lost revenue. Obviously there are some benefits - i.e. governments deliberately creating regulations that make competition difficult and essentially recreating protectionism while reaping the rewards of a free market, so I can see why it is a good thing, but it could easily be abused.
- romdev 9y agoA family member spends $450 US per month on Lyrica/pregabalin. I wonder if this patent decision could result in a rebate for individual patients.